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Clinically palpable thyroid nodules occur in 4–7% (Gharib, 1994;
Tezelman and Clark, 1995) of the population in the USA. A
German study showed that, in areas of iodine deficiency, thyroid
nodules are detected in up to 20% (Raue, 1995). In another study,
the incidence of thyroid carcinoma ranged from 0.5 to 10 cases per
100000 population (Schlumberger, 1998).
Thyroid cancers arise from follicular cells (papillary, follicular
and anaplastic carcinoma) and parafollicular epithelium
(medullary carcinoma). Diagnosis of thyroid carcinoma remains
difficult. The best method of distinguishing between benign and
malignant thyroid nodules, essential for operative decision-
making, is fine-needle aspiration cytology (Gharib, 1994;
Tezelman and Clark, 1995; Schlumberger, 1998). The major
problem of this procedure is the impossibility of differentiation
between follicular adenoma and follicular carcinoma because
capsular or venous tumour invasion cannot be detected.
At our department, 90 patients with papillary, 73 with follicular,
20 with anaplastic and 108 with medullary carcinoma of the
thyroid were treated surgically from 1987 until July 1998. In a
retrospective study (Weber et al, 1997) we demonstrated that a
correct preoperative diagnosis of thyroid cancer could only be
reached in 40% of these cases.
Moll et al (1990) described an intermediate filament group
protein cytokeratin 20 (CK20), contributing to differentiation and
function of the cytoskeleton of mucosal epithelia of the
mammalian gastrointestinal tract (Moll et al, 1992, 1993). In an
immunhistochemical analysis of 711 cases of primary and
metastatic cancer, CK20 was observed in adenocarcinomas of
colon and rectum, stomach, bile system and pancreas, ovarian
tumours, transitional-cell and Merkel-cell carcinomas (Moll et al,
1992). Papillary (n= 2) and follicular (n= 4) thyroid carcinomas
showed no expression of CK20. Medullary carcinoma stained
positive with CK20 antibodies (Moll et al, 1992).
In 1996, Schröder et al published an immunhistochemical study
in which he found an expression of CK20 in two of 27 medullary
carcinomas but no reactivity in papillary, follicular and anaplastic
thyroid carcinomas.
Polymerase chain reaction (PCR) increased the sensitivity of the
detection of circulating tumour cells and micrometastases in
peripheral blood up to 1 tumour cell in 106 normal cells (Ghossein
and Rosai, 1996; Gunn et al, 1996). Burchill et al 1995 was the
first to use CK20 reverse transcription PCR (RT-PCR) assays to
amplify CK20 transcripts as evidence for circulating tumour cells
in peripheral blood and bone marrow of patients with colorectal
cancer.
In this study we used a recently described CK20 RT-PCR
protocol (Weitz et al, 1998) to amplify CK20 transcripts from
thyroid carcinoma cell lines, frozen tissue sections of benign and
malignant thyroid diseases and peripheral blood of patients with
thyroid cancer in order to improve diagnosis of thyroid carcinoma
and to detect circulating tumour cells.
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SummaryWe investigated a nested reverse transcriptase polymerase chain reaction (RT-PCR) system to detect CK20 mRNA in thyroid
carcinomas, benign thyroid diseases and peripheral blood to improve diagnosis of thyroid carcinoma and to detect disseminated tumour cells.
Frozen tissue samples of 46 thyroid carcinomas and 30 benign thyroid diseases (14 multinodular goiters, 14 follicular adenomas, two
Hashimoto’s thyroiditis) were obtained intraoperatively. Preoperative blood samples were drawn from 31 patients with thyroid cancer, nine
patients with benign thyroid disorders and 20 healthy volunteers. Nine out of nine medullary, 9/12 follicular, 7/19 papillary and 2/6 anaplastic
carcinomas expressed CK20 transcripts. CK20 mRNA was undetectable in 30 tissue sections of benign thyroid diseases. Circulating tumour
cells were found in the blood of 3/8 patients with medullary carcinoma, 2/8 patients with follicular carcinoma, 2/11 patients with papillary
carcinoma and 1/4 patients with an anaplastic carcinoma. Nine blood samples of patients with benign thyroid diseases and 20 healthy
volunteers tested negative. For the first time CK20 mRNA could be detected in tissue sections of thyroid carcinomas and peripheral blood
samples of patients with thyroid cancer. It was not detectable in benign thyroid diseases. Our results therefore strongly suggest that
CK20 RT-PCR assays may improve the diagnosis of thyroid carcinoma and is able to detect circulating tumour cells in peripheral blood of
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Cell lines
Four well characterized thyroid carcinoma cell lines were used in
the study. They included the follicular carcinoma cell line FTC
133, the medullary cell line TT and two anaplastic cell lines SW
1736 and C 643.
Patient samples
Informed consent was obtained from all patients, and the study
protocol was approved by the ethics committee of the University
of Heidelberg. In case of suspected thyroid cancer, biopsy speci-
mens from consenting patients with benign and malignant thyroid
diseases were obtained intraoperatively during subtotal or total
thyroidectomy at the Department of Surgery of the University of
Heidelberg, immediately snap-frozen in liquid nitrogen and stored
at –70°C.
Peripheral blood samples (10 ml, EDTA) were drawn from
healthy volunteers and preoperatively from patients undergoing
surgery for benign and malignant thyroid diseases. Patients with
known secondary malignancies were excluded from the study.
After dilution with 10 ml phosphate-buffered saline (PBS) and
density centrifugation through Ficoll-Paque (Pharmacia),
mononuclear blood cells were harvested and washed twice in PBS.
The cell pellet was snap-frozen in liquid nitrogen and stored at
–70°C.
RNA extraction
Total RNA from cell lines, frozen tissue sections of benign thyroid
diseases and thyroid carcinomas and mononuclear blood cells was
extracted using a commercially available RNA extraction kit
(Trizol Reagent, Life Technologies, Inc., Karlsruhe, Germany).
RT-PCR
CK20 RT-PCR was essentially performed as described by Weitz
et al (1998). Briefly, cDNA was synthesized using a reverse
transcription kit (Life Technologies, Inc.) and the primer CK20
558.rev.
PCR was performed in 50-ml samples that contained a final
concentration of 25 pmol each primer, 0.2 mM each NTP, 1.5 mM
magnesium chloride, 2.5 units Taq polymerase and 20 mM PCR
buffer (PCR kit: Life Technologies, Inc.). For the first PCR 2.5 ml
cDNA was used to amplify CK20 cDNAs with the primers 1.for
(ATGGATTTCAGTCGCAGA) and 558.rev (ATGTAGGGTTAG-
GTCATCAAAG). Thirty-five rounds of amplification were
performed at 30-s intervals at temperatures of 93°C, 60°C and
72°C. The nested PCR was performed with 10 ml PCR product of
the first PCR with primer 139.for (TCCAACTCCAGACACACG-
GTGAACTATG) and 429.rev (CAGGACACACCGAGCATT-
TTGCAG) under the amplification conditions as described for the
first PCR with an annealing temperature of 72°C. PCR products
were analysed by electrophoresis on 2% agarose gels. In addition,
direct thermocycle sequencing and in situ hybridization of the
obtained amplimere was performed.
Sensitivity
The sensitivity of the CK20 RT-PCR assay was determined in dilu-
tion experiments using the medullary thyroid carcinoma cell line
TT and the colon cancer cell line HT29. Tumour cells (0, 10, 102,
103, 104, 105) were added to 10 ml of peripheral blood samples of
healthy donors, mRNA extracted and RT-PCR was performed for
CK20.
Northern blot
mRNA was separated on 0.8% MOPS agarose gels and blotted to
Hybond N Plus membranes. PolyA Plus mRNA was transferred to
Hybond N Plus (Amersham, Little Chalfont, UK) membranes.
Nested CK20 PCR products were labelled with (Alpha-32P)-dCTP
using the random primed cDNA labelling kit from MBI Fermentas
(Amherst, NY, USA). These filters were hybridized with labelled
CK20 probes according to standard protocols.
RESULTS
Sensitivity of CK20 RT-PCR
A 290-bp PCR product was amplified from samples enriched with
TT cells up to a dilution of 105 TT cells in 10-ml peripheral blood.
As previously described (Weitz et al, 1998) CK20 transcripts from
blood samples enriched with HT 29 cells, a colon carcinoma cell
line, could be detected up to a dilution of ten HT 29 cells in 10 ml
blood. Direct thermocycle sequencing confirmed that the 290-bp
amplimere corresponded to amplified CK20 cDNA fragments.
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Figure 1 Detection of CK20 mRNA in thyroid carcinoma tissue (n = 46)
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Figure 2 CK20 RT-PCR amplification products in tissue sections of
papillary, follicular, medullary and anaplastic thyroid carcinoma. N, negative
controls; M, molecular weight marker (100 bp); P, positive control (TT cell
line). Lanes 2–4, no detection of CK20 mRNA in 3 papillary carcinomas;
lanes 5–7, CK20 amplification in two of three follicular carcinomas; lanes
8–10, positive results for three of three medullary carcinomasA Northern blot analysis was performed to compare the levels
of CK20 mRNA expression in TT and HT 29 cells quantitatively.
A significantly stronger CK20 hybridization signal was obtained
in the colon carcinoma cell line HT 29 compared to the medullary
carcinoma cell line TT could be demonstrated.
Specifity of CK20 RT-PCR
In line with previous reports CK20 RT-PCR products could not be
detected in 20 of 20 control blood samples from healthy volun-
teers. The integrity of mononuclear blood cell RNA was
confirmed by RT-PCR for glyceraldehycle 3-phosphate dehydro-
genase (GAPDH).
Thyroid carcinoma cell lines
Three (TT, SW 1736, C 643) of four human thyroid carcinoma cell
lines expressed CK20 mRNA, as demonstrated by amplification of
the 290-bp CK20 transcript. The follicular carcinoma cell line
FTC 133 tested negative.
Benign and malignant thyroid tissue
CK20 mRNA was undetectable in 30 benign thyroid tissue
sections (14 multinodular goiters, 14 follicular adenomas and two
cases of Hashimoto’s thyroiditis). CK20 transcripts were amplified
in 9/9 (100%) medullary carcinomas, 9/12 (75%) follicular carci-
nomas, 7/19 (37%) papillary thyroid carcinomas and 2/6 (33%)
anaplastic carcinomas (Figures 1 and 2).
Peripheral blood samples
Nine out of nine blood samples of patients with benign thyroid
diseases (five multinodular goiters, four follicular adenomas)
tested negative for CK20 RT-PCR.
Peripheral blood samples could be obtained from 31 of 46
patients with thyroid cancer. CK20 mRNA could not be detected
in 12 blood samples which were obtained from 19 patients whose
tumours did not express CK20 transcripts.
Eighteen blood samples were derived from 27 patients with
carcinomas positive in the CK20 RT-PCR assay. Due to the histo-
logical classification of the tumours the following results could be
demonstrated: CK20 mRNA was detected in peripheral blood
samples of 3/8 patients with medullary carcinoma, 2/6 with follic-
ular carcinoma 2/4 with papillary thyroid carcinoma and one
patient with an anaplastic carcinoma (Table 1). In the cases of
medullary carcinoma the CK20 mRNA-positive samples were
obtained from one patient with an advanced medullary carcinoma
staged pT4N1bM0 and two patients with local recurrence of
medullary thyroid cancer. In the two blood samples of patients
with follicular carcinomas and detectable CK20 transcripts the
tumour stages were classified histologically as pT2N0M0 and
pT4N1bM1 (lung metastases). In case of papillary carcinoma the
blood samples tested positive for CK20 mRNA were obtained
from a patient with a pT2N0M0 tumour and a patient with local
recurrence (Table 2).
DISCUSSION
According to the literature a number of thyroid-specific tumour
markers such as thyroglobulin (Ringel et al, 1998; Tallini et al,
1998; Weber et al, 1998), thyroid peroxidase (Tallini et al, 1998)
and the human sodium-iodine symporter (Smanik et al, 1997) were
investigated in order to establish a molecular diagnosis of thyroid
carcinoma. However, the common problem of all of these PCR
systems was a high rate of false-positive results. RNA of
thyroglobulin (Ringel et al, 1998; Weber et al, 1998), thyroid
peroxidase and the sodium-iodine symporter (unpublished data)
was detected in blood samples of healthy volunteers. Recently,
Ringel et al (1998) demonstrated that normal thyroid cells can be
detected in peripheral blood samples. The concept of our study
therefore was not to establish a thyroid-specific marker, but a
tumour-specific marker, which is expressed by thyroid carcinoma
cells because of a different gene expression in malignant trans-
formed cells.
The detection of circulating tumour cells with CK20 RT-PCR
in peripheral blood and bone marrow of patients with primary
carcinomas and their metastases such as colorectal cancer
(Burchill et al, 1995; Gunn et al, 1996; Soeth et al, 1997; Wertz
et al, 1998; Wyld et al, 1998), stomach cancer (Soeth et al, 1997),
pancreatic cancer (Soeth et al, 1997) and bladder carcinoma (Klein
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Table 1 Expression of CK20 mRNA in preoperative blood samples of
patients with thyroid carcinoma (n = 31)
Histology Positive results
Medullary carcinoma 3/8 (38%)
Follicular carcinoma 2/8 (25%)
Papillary carcinoma 2/11 (18%)
Anaplastic carcinoma 1/4 (25%)
Total 8/31 (26%)
Table 2 Detection of circulating tumour cells in peripheral blood of patients
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Figure 3 Detection of CK20 mRNA in preoperative blood samples of
patients with thyroid carcinoma. N, negative contrils; M, molecular weight
market (100 bp); P, positive control (TT cell line). Lanes 2–4, no detection of
CK20 mRNA in three blood samples of patients with papillary carcinoma;
Lanes 5–7, detection in CK20 in one of three patients with follicular
carcinoma; Lanes 8–10, detection of CK20 in two of three patients with
medullary carcinoma
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GAPDHet al, 1998) has created a new way of understanding the mecha-
nisms of recurrent disease. Nevertheless, the correlation between
tumour progression or prognosis is still controversial. While Wyld
et al (1998) could not find a correlation for patients with colorectal
cancer, Soeth et al (1997) described a statistically proven shorter
survival for patients with colorectal and stomach cancer who
tested positive for CK20 mRNA in blood and bone marrow
samples. Investigations of cytokeratin markers in thyroid carci-
nomas have been published by Moll et al (1992) and Schröder et al
(1996). Using an immunhistochemical assay they found an expres-
sion of CK20 in 1/1 (Moll et al, 1992) and 2/27 (Schröder et al,
1996) medullary carcinomas respectively.
Since the sensitivity of RT-PCR in detecting CK20 mRNA is
much higher, we established this method to investigate thyroid
tumours. We demonstrated an expression of CK20 mRNA in a
medullary (TT) and two anaplastic (SW 1736, C 643) thyroid
carcinoma cell lines. Compared to the colon carcinoma cell line
HT29, TT cells, however, showed a weaker expression of CK20 in
a Northern blot examination.
CK20 mRNA was detected in primary and recurrent thyroid
carcinomas depending on the histological classification of the
tumours. All of the nine medullary carcinomas, 9/12 follicular
carcinomas, 7/19 papillary carcinomas and 2/6 anaplastic carci-
nomas showed an amplification of CK20 transcripts. In one case a
papillary carcinoma (pT4N0M0) tested negative for the primary
tumour and positive for the recurrent disease, which occurred 1
year after total thyroidectomy. An explanation for this obvious
difference in expressing CK20 may be a shift of the tumour into a
lower grade of differentiation and a greater transcriptional relax-
ation of the recurrent tumour.
To detect circulating tumour cells, we examined peripheral
blood samples obtained from 19 of 27 patients with thyroid carci-
nomas tested positive for CK20. An expression of CK20 mRNA in
peripheral blood could be demonstrated in three of eight cases of
medullary carcinoma, two of six patients with follicular carci-
nomas, two of four patients with papillary carcinomas and one
patient with an anaplastic carcinoma. The sensitivity for detecting
CK20 mRNA in peripheral blood of patients with CK20-positive
carcinomas was 42% (8/19 blood samples tested positive), the
sensitivity for all tested blood samples was 26% (8/31). Since the
number of examined blood samples divided into four different
histological types of thyroid carcinoma is relatively small, a
correlation between the detection of circulating tumour cells and
the stage of the disease is only shown for medullary carcinomas
(Table 2).
CK20 mRNA was undetectable in 30 tissue sections of multi-
nodular goiters, follicular adenomas and Hashimoto’s thyroiditis.
Twenty blood samples from healthy volunteers, nine blood
samples of patients with benign thyroid diseases and 12 blood
samples of patients with CK20-negative carcinomas tested consis-
tently negative in CK20 PCR. Since there were no false-positive
results, the specificity reached 100%.
We hypothesized that CK20 RT-PCR may contribute in
improving preoperative diagnosis of thyroid cancer. Our results
showed for the first time that CK20 mRNA can be detected in
thyroid carcinoma tissue and preoperative blood samples of cancer
patients but not in tissue and blood samples of patients with benign
thyroid disorders. These preliminary results and their clinical
value will be continuously evaluated on a larger group of patients,
observed over a longer period of time.
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